Video

(AAO) Comparing outcomes of xen gel stents in glaucoma practice

Author(s):

Alex Delaney-Gesing ,David Hutton
Conferences|AAO

Davinder Grover, MD, MPH, speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice.


During AAO 2020, Davinder Grover, MD, MPH, glaucoma specialist, Glaucoma Associates of Texas speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice.

See more AAO coverage here

Related Videos
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
AAO 2024: Weijie Violet Lin, MD, discusses risk factors for epithelium-off cross-linking
Related Content
SpyGlass Pharma completes enrollment in Phase I/II study of its long-term drug delivery platform for glaucoma and ocular hypertension
November 19th 2024

SpyGlass Pharma completes enrollment in Phase I/II study of its long-term drug delivery platform for glaucoma and ocular hypertension

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

MediPrint Ophthalmics reveals positive results from phase 2b study of LL-BMT1 contact lens
November 12th 2024

MediPrint Ophthalmics reveals positive results from phase 2b study of LL-BMT1 contact lens

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

The top 10 takeaways from AAO 2024
October 23rd 2024

The top 10 takeaways from AAO 2024

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function
October 22nd 2024

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function

© 2024 MJH Life Sciences

All rights reserved.